Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGINTERVENTIONAL

Biannual Review of Exhaled Air and Trends in Health Evaluation in COPD

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This study aims to evaluate how airway inflammation, lung function, and symptoms change over time in people with chronic obstructive pulmonary disease (COPD). Airway inflammation will be assessed using a simple breath test (FeNO) and a small blood sample to measure eosinophils, a type of white blood cell. Participants will be followed for one year, with three study visits (at the start, 6 months, and 12 months). The goal is to understand how these markers evolve and whether they differ between people who experience a worsening of symptoms (called exacerbations) and those who remain stable. All tests except for a small extra blood draw are part of routine COPD care. Participation does not affect standard treatment.

Who May Be Eligible (Plain English)

Who May Qualify: - Adults aged ≥ 40 years - Diagnosed with COPD according to GOLD criteria - Attending routine follow-up visits every 6 months - Ability to provide willing to sign a consent form Who Should NOT Join This Trial: - Recent respiratory tract infection or exacerbation (either moderate or se-vere) (\<4 weeks before inclusion) - Dominant asthmatic phenotype (ACO with asthma predominance) - Severe comorbidities interfering with participation or follow-up Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Adults aged ≥ 40 years * Diagnosed with COPD according to GOLD criteria * Attending routine follow-up visits every 6 months * Ability to provide informed consent Exclusion Criteria: * Recent respiratory tract infection or exacerbation (either moderate or se-vere) (\<4 weeks before inclusion) * Dominant asthmatic phenotype (ACO with asthma predominance) * Severe comorbidities interfering with participation or follow-up

Treatments Being Tested

DIAGNOSTIC_TEST

Blood eosinophil Count

Blood sample for blood eosinophil count

Locations (1)

Universitair Ziekenhuis Brussel
Jette, Belgium